金吾财讯 | 浦银国际发研报指,再鼎医药(09688)1Q25实现1.065亿美元产品总收入(+22.2%YoY,-2.4%QoQ)、1.057亿美元产品净收入(+21.2%YoY,-2.6%QoQ),略低于该行预期及VisibleAlpha(VA)一致预期,主要由于核心产品艾加莫德收入略低于预期;净亏损缩窄至4,844万美元(-9.4%YoY,-40.7%QoQ),好于VA预期和该行预期,主要...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.